Meta-analysis of lobectomy and sublobar resection for stage I non-small cell lung cancer with spread through air spaces

Author(s):  
Jialong Li ◽  
Yan Wang ◽  
Jue Li ◽  
Shangqi Cao ◽  
Guowei Che
2021 ◽  
Author(s):  
Yong Li ◽  
Fang Yang ◽  
Ya-Yong Huang ◽  
Tao Wang

Abstract BackgroundStage I non-small-cell lung cancer (NSCLC) can be treated by both ablation and sublobar resection (SR). This meta-analysis was therefore designed to better compare the relative safety and efficacy of these two approaches to treating stage I NSCLC.Materials and MethodsRelevant studies published through November 2020 in the Cochrane Library, Embase, and PubMed databases were identified for analyses which were conducted with RevMan v5.3. ResultsIn total, 816 potentially relevant articles were identified, of which 8 were ultimately included in the final meta-analysis. Patients in the SR group exhibited a signficantly lower pooled local recurrence (LR) rate (5.0% vs. 25.4%, P < 0.0001), although pooled distant recurrence (DR) rates were similar in both groups (25.7% vs. 23.1%, P = 0.75). The pooled hazard ratio (HR) for overall survival (OS) (HR: 1.23; 95% CI: 1.13-1.33, P < 0.00001), progression-free survival (PFS) (HR: 1.34; 95% CI: 1.15-1.55, P = 0.0002), and cancer-specific survival (CSS) (HR: 1.39; 95% CI: 1.15-1.70, P = 0.0009) all indicated better survival outcomes among patients that underwent HR treatment, while pooled complication rates were similar in both groups (27.7% vs. 43.8%, P = 0.27). Patients that underwent ablation exhibited significantly shorter pooled post-operative hospitalization relative to those in the SR group (MD: 5.93; 95% CI: 0.78-11.07, P = 0.02). No evidence of publication bias was detected through funnel plot analyses.ConclusionsSR treatment of stage I NSCLC patients was associated with a lower LR rate and longer survival as compared to ablation.


2017 ◽  
Vol 9 (6) ◽  
pp. 1615-1623 ◽  
Author(s):  
Benedetta Bedetti ◽  
Luca Bertolaccini ◽  
Raffaele Rocco ◽  
Joachim Schmidt ◽  
Piergiorgio Solli ◽  
...  

2020 ◽  
Vol 57 (6) ◽  
pp. 1051-1060 ◽  
Author(s):  
Thomas Winckelmans ◽  
Herbert Decaluwé ◽  
Paul De Leyn ◽  
Dirk Van Raemdonck

Abstract OBJECTIVES The role of segmentectomy in early-stage non-small-cell lung cancer (NSCLC) remains a matter of debate. We performed a meta-analysis to evaluate the oncological outcomes following segmentectomy versus lobectomy for stage I, stage IA only and stage IA &lt;2 cm only. METHODS We systematically searched the literature for articles reporting on overall survival (OS), cancer-specific survival (CSS) or recurrence-free survival (RFS). The hazard ratios (HRs) were retrieved and pooled using an inverse variance-weighted approach. RESULTS Twenty-eight studies were included in the analysis. In stage I, segmentectomy was found to be inferior to lobectomy for all 3 outcomes with HR: 1.25 (P = 0.01) for OS, 1.59 (P = 0.02) for CSS and 1.40 (P &lt; 0.001) for RFS. In stage IA, the differences were significant for OS and CSS, though not for RFS with HR: 1.31 (P = 0.04), 1.56 (P = 0.02) and 1.22 (P = 0.11), respectively. In stage IA &lt;2 cm, no significant differences were found between segmentectomy and lobectomy with HR: 1.13 (P = 0.37) for OS, 1.02 (P = 0.95) for CSS and 1.24 (P = 0.11) for RFS. CONCLUSIONS For stages I and IA, lobectomy showed superior results whereas for tumours &lt;2 cm, our study did not find significant differences in oncological outcomes between both groups. These results suggest that segmentectomy might be a valuable alternative to lobectomy for NSCLC in tumours &lt;2 cm.


2018 ◽  
Vol 106 (2) ◽  
pp. 354-360 ◽  
Author(s):  
Satoshi Shiono ◽  
Makoto Endo ◽  
Katsuyuki Suzuki ◽  
Kei Yarimizu ◽  
Kazuki Hayasaka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document